Guibao, Renierose .
HRN: 24-68-36 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
03/11/2024
CO-AMOXICLAV 625MG (TAB)
03/11/2024
03/18/2024
PO
625
BID
Thickly MSAF
Waiting Final Action
Indication: Empiric Type of Infection: Skin & Soft TissueReproductive Tract Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes